BioSpace News Archive

OpenEye Scientific and Specifica, Inc., announced they are releasing jointly developed software to help antibody engineers and bioinformaticians at pharmaceutical and biotechnology companies advance antibody discovery by identifying diverse antibody sets with better properties for downstream therapeutics development.

Tevogen Bio today announced TVGN-489, its lead investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTL) immunotherapy for treatment of COVID-19 in high-risk patients, is expected to retain activity against the B.1.1.529, or Omicron variant.

Vifor Pharma Group systematically reviews options that can strengthen its market position and/or accelerate the growth of the company both organically and through partnerships and acquisitions.

Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announces that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB – IV melanoma.

Development of it’s own pipeline products with potential for the Company to secure a number of patents covering revolutionary Car-T bi-specific therapies in the near term.

The global hemodynamic monitoring devices market size is expected to reach USD 1,566.7 Million at a steady CAGR of 6.1% in 2028.

Sound Life Sciences, a pioneer in contactless respiratory monitoring with its proprietary sonar software for consumer smart devices, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, announced today that it will report first quarter 2022 financial results on Wednesday, December 15, 2021, after the market close.

Context Therapeutics Inc. (Nasdaq: CNTX), today announced financial results for the third quarter ended September 30, 2021, and highlighted recent corporate accomplishments.

Dynavax Technologies Corporation reported that it has granted nonstatutory stock options to purchase an aggregate of 58,500 shares of Dynavax common stock as inducements to 5 newly-hired employees in connection with commencement of employment with the Company.